tiotropium-bromide

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

AsthmaCOPD

Phase 2

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

CompletedNCT01634113

Boehringer IngelheimAsthma

Start: 2012-07-31End: 2014-12-31Updated: 2015-06-23

Unknown Phase

RUSSE / Russian Spiriva® Safety & Efficacy Study

CompletedNCT00613574

Boehringer IngelheimCOPD

End: 2007-10-31Updated: 2014-04-10

Related Papers

Safety of tiotropium Respimat<sup>®</sup> in black or African-American patients with symptomatic asthma.

2019-07-022 citations

P45 Effect of tiotropium respimat® on seasonal asthma worsening in paediatric patients

2018-11-161 citations

In vitro and clinical characterization of the valved holding chamber AeroChamber Plus® Flow-Vu® for administrating tiotropium Respimat® in 1–5-year-old children with persistent asthmatic symptoms

Respiratory Medicine2018-03-0812 citations

Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial.

2018-01-1843 citations

Safety and Efficacy of Tiotropium Respimat® Add-on Therapy in Pre-school Children with Symptomatic Persistent Asthma

PEDIATRICS2018-01-01

P86 In vitro and clinical characterisation of the antistatic valved holding chamber aerochamber plus® flow-vu® for administrating tiotropium respimat® in 1–5-year-old children with persistent asthmatic symptoms

2017-11-15

P154 Safety of tiotropium in pre-school children with symptomatic persistent asthma

Thorax2016-11-151 citations

Safety of tiotropium in pre-school children with symptomatic persistent asthma

2016-09-018 citations

Pharmacokinetics of tiotropium in asthma patients from three paediatric clinical trials

2016-09-013 citations